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SHOULD OUR GENES BE PART OF THE PATENT
BARGAIN? MAXIMIZING ACCESS TO MEDICAL
DIAGNOSTIC ADVANCES WHILE ENSURING RESEARCH
REMAINS PROFITABLE
Johanna Jacob†
I.

INTRODUCTION

The purpose of the United States patent system is “[t]o promote
the Progress of Science and useful Arts.”1 Currently, there is a heated
emotional debate about whether patents directed to genetic sequences
promote or hinder the progress of science, a debate which may soon
find its way to the United States Supreme Court.2 Unfortunately, the
debate is too often characterized in terms of policy concerns. In
Association for Molecular Pathology v. United States Patent and
Trademark Office, Judge Sweet broke with three decades of United
States Patent and Trademark Office (USPTO) precedent,3 declaring
the method and system claims to the genetic sequences of BRCA1

† Johanna Jacob, Santa Clara Law Student, J.D. Expected May 2012. This comment
was selected as the winner of the 2010-2011 Santa Clara Computer & High Technology Law
Journal Comment Competition.
†† As this issue went to press, the Supreme Court released its opinion in the Mayo v.
Prometheus case. Mayo Collaborative Servs. v. Prometheus Labs., Inc., No. 10-1150, slip op.
(U.S. Mar. 20, 2012), available at http://www.supremecourt.gov/opinions/11pdf/10-1150.pdf.
Shortly after, in the Molecular Pathology v. Myriad Genetics case the Supreme Court granted
the petition for certiorari, vacated the Federal Circuit judgment, and remanded for
reconsideration in light of the Prometheus decision. Cert. Summ. Dispositions at 2, Ass’n for
Molecular Pathology v. Myriad Genetics, No. 11-725 (U.S. Mar. 26, 2012) (previously entitled
Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office).
1. U.S. CONST. art. I, § 8, cl. 8.
2. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp.
2d 181, 185 (S.D.N.Y. 2010), aff’d in part, rev’d in part, 653 F.3d 1329 (Fed. Cir. 2011); see
also Liberate the Breast Cancer Genes, AM. CIVIL LIBERTIES UNION (Mar. 29, 2010),
http://www.aclu.org/free-speech_womens-rights/liberate-breast-cancer-genes (varying opinions
on the patentability of genetic sequences).
3. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329,
1367 (Fed. Cir. 2011) (Moore, J., concurring) (“Even before the current guidelines formalized
the Patent Office’s position, however, it granted patents to human genes in the early 1980s, and
subsequently issued thousands of patents on ‘isolated DNA.’”).
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and BRCA2 ineligible for patents.4 Judge Sweet created a blanket
exception to 35 U.S.C. §101 by characterizing genes under the “law
of nature” exception to patentability.5 Myriad Genetics Inc. (Myriad)
appealed, and the Federal Circuit Court of Appeals ruled on July 29,
2011.6 The Federal Circuit reversed Judge Sweet’s ruling by
upholding claims directed to isolated genetic sequences as subject
matter eligible for patenting under 35 U.S.C. §101.7 However, the
Federal Circuit invalidated diagnostic method claims that merely
compared a genetic sequence to an individual’s native genetic
sequence as an abstract mental process.8 Both parties filed a petition
for rehearing in the Federal Circuit.9
The real issue in Association for Molecular Pathology is patient
access to health care, which should not be achieved through a
judicially-created exception to the statutory definition of patent
eligible subject matter. While the Federal Circuit focuses on the
science, the underlying issues largely guide their interpretation. It is
unlikely that agreement on the science and how it applies to patent
eligible subject matter will ever be achieved. Judge Moore, in his
concurring opinion, rightly states that it is the policy that tips the
scales towards patentability.10
Weakening biotechnology patent law by declaring claims to
genetic sequences patent ineligible, as products of nature under 35
U.S.C. §101, would negatively impact patient access to biotechnology
advances by decreasing the incentive of investors to enter the market
more than it could possibly help promote patient access to BRCA1

4. Ass’n for Molecular Pathology, 702 F. Supp. 2d at 185.
5. Id. at 237 (“As determined above, the patents issued by the USPTO are directed to a
law of nature and were therefore improperly granted.”).
6. Ass’n for Molecular Pathology, 653 F.3d at 1329.
7. Id. at 1334.
8. Id. at 1334.
9. Plaintiffs-Appellees’ Petition for Panel Rehearing, Ass’n for Molecular Pathology v.
U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011) (No. 2010-1406), 2011 WL
5057016; Defendants-Appellants’ Petition for Panel Rehearing, Ass’n for Molecular Pathology
v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011) (No. 2010-1406), 2011 WL
5057015.
10. Ass’n for Molecular Pathology, 653 F.3d at 1367 (Moore, J., concurring) (“I believe
we must be particularly wary of expanding the judicial exception to patentable subject matter
where both settled expectations and extensive property rights are involved. Combined with my
belief that we should defer to Congress, these settled expectations tip the scale in favor of
patentability.”).
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and BRCA2 diagnostic technologies. Patient access to second
opinions, affordable diagnostic technologies, patient counseling,
comprehensive genetic testing, and insurance coverage are not aspects
of patent law, and are best addressed through meaningful health care
reform.
II. BACKGROUND
A. 35 U.S.C. §101 Patentable Subject Matter
Patentable subject matter, the threshold test for patentability, is
defined as “any new and useful process, machine, manufacture, or
composition of matter, or any new and useful improvement thereof.”11
The statute on patentable subject matter, 35 U.S.C. §101, is given
broad meaning through the use of the word “any” in describing the
type of new and useful processes that are patentable, the legislative
history surrounding its enactment, and the interpretation that
“anything under the sun that is made by man” is patentable.12 The
proper forum for excluding a specific subject matter from the patent
bargain lies with Congress in the legislative body and not the
judiciary.13
However, courts recognize some subject matter as ineligible for
patentability under 35 U.S.C. §101. Exceptions to patentable subject
matter include laws of nature, physical phenomena, and abstract
ideas.14 Products of nature should be “free to all men and reserved
exclusively to none.”15 Laws of nature, physical phenomena, and
abstract ideas are recognized as a type of scientific discovery, rather
than a novel invention. This promotes the policy that a discovery is
left to the public domain while an invention benefits from intellectual

11.
12.
13.

35 U.S.C. § 101 (2006).
35 U.S.C. § 101 (2006); Diamond v. Chakrabarty, 447 U.S. 303, 307-309 (1980).
See Chakrabarty, 447 U.S. at 318.
Our task, rather, is a narrow one of determining what Congress meant by the
words it used in the statute; once that is done our powers are exhausted. Congress
is free to amend §101 so as to exclude from patent protection organisms
produced by genetic engineering. . . . But, until Congress takes such action, this
Court must construe the language of §101 as it is.

Id.
14.
15.

Id. at 309.
Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948).
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property rights.16
The line between scientific discovery and invention blurs when
patent law and biotechnology intersect. In 1948, the Supreme Court
held a combination fertilizer with several different naturally occurring
bacteria unpatentable, because a natural material, even if combined in
a novel fashion, will still be ineligible for patentability if the
functionality of the material would occur naturally.17 Later, in
Chakrabarty, the Supreme Court held that a genetically modified
bacterium engineered to break down crude oil is a “non[-]naturally
occurring manufacture or composition of matter” and therefore
patentable.18 The test articulated in Chakrabarty was whether the nonnaturally occurring composition of matter was a product of human
ingenuity with “distinctive name, character and use.”19 Therefore a
composition of matter must be: (1) non-naturally occurring; (2)
product of ingenuity; with (3) distinctive name, character and use.20 In
finding that the bacteria met that standard of law, the court remarked
that the patentee had produced a new bacterium with “markedly
different characteristics” from the product as it occurred in nature,
with the potential for significant utility.21 After Chakrabarty, patents
on genetic sequences were held to be patentable and over 4,000
patents on genes were issued.22
The Supreme Court addressed the patentability of an isolated
substance in The American Wood-Paper Co v. Fibre Disintegrating
Co.23 The Court held purified cellulose is a mere “extract” and is not a
new manufacture subject to patentability.24 In contrast, the
patentability of a purified naturally-occurring biological compound
was addressed by a district court in New York in 1912.25 Judge
16. See Parker v. Flook, 437 U.S. 584, 593 (1978).
17. Funk Bros., 333 U.S. at 131.
18. Chakrabarty, 447 U.S. at 309-10.
19. Id. at 309-10.
20. Id.
21. Id. at 310.
22. Denise Caruso, A Challenge to Gene Theory, a Tougher Look at Biotech, N.Y. TIMES
(July 1, 2007),
https://www.nytimes.com/2007/07/01/business/yourmoney/01frame.html?pagewanted=all.
23. Am. Wood-Paper Co. v. Fibre Disintegrating Co., 90 U.S. (23 Wall.) 566, 593-94
(1874).
24. Id. at 594.
25. Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95, 103 (C.C.S.D.N.Y. 1911), aff’d
in part, rev’d in part, 196 F. 496 (2d Cir. 1912).
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Learned Hand found isolated purified adrenaline to be patentable.26 A
purified base form of a component was found to be a new thing, both
therapeutically and chemically, because it functioned differently in its
purified form than it did in nature.27 Currently, courts follow Judge
Hand’s 1912 ruling in Parke-Davis for guidance on the patentability
of isolated, naturally-occurring biological substances.28
B. What Are Genes?
“Genes are the ‘basic units of heredity’ that enable organisms to
transmit to future generations the blueprint for all proteins.”29 Genes
contain the hidden plans and design for development of an
organism.30 Deoxyribonucleic acid (DNA) is the carrier of genetic
information, and it is a long unbranched polymer composed of four
bases: adenine, cytosine, guanine, and thymine.31 The bases are
attached to a repetitive sugar phosphate chain through chemical
bonds, like beads strung to a necklace.32 DNA normally exists as a
two-strand “double helix.”33 Each base is bound to its complementary
base pair, A-T ad G-C. Therefore, when the double helix splits, each
strand of the double helix can create its own copy of the original
double helix.34 The linear order of the nucleotide bases (A, T, G and
C) is referred to as the genetic sequence.35 The human genetic
sequence would fill a book of more than 500,000 pages written in the
four-letter genetic alphabet.36
The sections of the DNA strand that encode to form proteins or
functional molecules are known as genes; not every part of the DNA

26. Id.
27. Id.
28. Lisa Larrimore Ouellette, Note, Access to Bio-Knowledge: From Gene Patents to
Biomedical Materials, 2010 STAN. TECH. L. REV. ¶ 13 (2010).
29. Brief for the United States as Amicus Curiae Supporting Neither Party, Ass’n for
Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011) (No.
2010-1406), 2010 WL 4853320.
30. BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL 98 (3d ed. 1994).
31. Id.
32. Id. at 98-99.
33. See id. at 99.
34. Id. at 102.
35. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329,
1336 (Fed. Cir. 2011).
36. BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL 102 (3d ed. 1994).
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strand codes for a gene.37 The human genome contains approximately
3 billion base pairs, and almost every cell in the human body contains
a complete genome.38 Human DNA is arranged into 24 distinct
chromosomes, which are physically separate molecules ranging in
length from 50-250 million base pairs, with each chromosome
containing many genes.39 There are approximately 20,000-25,000
genes, which together contain the physical and functional traits that
form a human being.40
Ribonucleic Acid (RNA) is like DNA, in that it is a chain of
linked nucleotides.41 However, the RNA molecule is single stranded,
composed of the sugar ribose instead of deoxyribose, and consists of
the nucleotides adenine, guanine, uracil (which replaces the thymine
found in DNA) and cytosine.42 Messenger RNA (mRNA) is a type of
RNA that transfers the information about DNA’s amino acid
sequence to the protein synthesis process.43 Complementary DNA
(cDNA) is a molecule generated from mRNA through “reverse
transcription.”44 Each base in the cDNA is complementary to the
corresponding base in the mRNA it is generated from; and therefore,
it contains the same informational content as the original DNA
molecule. cDNA is typically generated in a laboratory.45 Unlike
DNA, cDNA does not contain the non-coding sequences because they
37.

BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL 104 (3d ed. 1994).
The synthesis of proteins involves copying specific regions of DNA (the genes)
into polynucleotides of a chemically and functionally different type known as
ribonucleic acid, or RNA. . . . Molecules of RNA are synthesized by a process
known as DNA transcription, which is similar to DNA replication in that one of
the two strands of DNA acts as a template on which the base-pairing abilities of
incoming nucleotides are tested.

Id.
38. The Human Genome Project, The Science Behind the Human Genome Project: Basic
Genetics, Genome Draft Sequence, and Post-Genome Science, OAK RIDGE NAT’L LAB.,
http://www.ornl.gov/sci/techresources/Human_Genome/project/info.shtml (last modified Mar.
26, 2008).
39. Id.
40. Id.
41. RNA Transcription, NOBEL FOUNDATION,
http://www.nobelprize.org/educational/medicine/dna/b/transcription/rna_strand.html (last visited
Feb. 28, 2012).
42. Id.
43. Id.
44. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d
181, 198 (S.D.N.Y. 2010).
45. Id.
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were removed in the creation of the mRNA.46
“Isolated DNA” is the result of a laboratory process where the
DNA molecule is excised from the genome and separated from its
cellular environment.47 Courts typically hold that products of nature
are different from products that have been altered or enhanced
through processes of extraction, concentration, and purification of
natural materials.48 Isolation is a form of extraction, which may cause
genetic sequence patents to cross the line from patent ineligible to
patentable.49
Although isolation usually tips the scale towards patentability,
DNA sequencing methods are rapid and reliable.50 DNA has become
the easiest macromolecule of the cell to analyze.51 It is currently
possible to excise a specific region of DNA, produce a virtually
unlimited amount of copies, and to determine the sequence of the
nucleotides at a rate of hundreds of nucleotides a day. 52 In order to
sequence a gene, a chromosome is first broken into much shorter
segments through subcloning.53 Templates are generated by creating
fragments that differ in length by a single base, and these fragments
are then separated by gel electrophoresis.54 The final base at the end
of each fragment is identified, recreating the 4 letter genetic alphabet
base by base.55 As scientists’ knowledge of this process and
capabilities rapidly evolved, patent applications on human genes were

46. Id.
47. Brief for the United States as Amicus Curiae Supporting Neither Party at 3,
Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir.
2010) (No. 2010-1406), 2010 WL 4853320, at *3.
48. See id. at 35-36.
49. See id.
50. BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL 291 (3d ed. 1994).
From being the most difficult macromolecule of the cell to analyze, DNA has
become the easiest. It is now possible to excise a specific region of DNA, to
produce a virtually unlimited number of copies of it, and to determine the
sequence of its nucleotides at a rate of hundreds of nucleotides a day.
Id.
51. Id.
52. Id.
53. The Human Genome Project, The Science Behind the Human Genome Project: Basic
Genetics, Genome Draft Sequence, and Post-Genome Science, OAK RIDGE NAT’L LAB.,
http://www.ornl.gov/sci/techresources/Human_Genome/project/info.shtml (last modified Mar.
26, 2008).
54. Id.
55. Id.
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filed in increasing numbers.56
III. ASSOCIATION FOR MOLECULAR PATHOLOGY V. U.S. PATENT
AND TRADEMARK OFFICE: THE CONTROVERSY AND
UNDERLYING ISSUES
Myriad’s patents are controversial for several reasons. First,
Myriad’s patents deal with breast cancer—a widespread disease that
crosses all racial and socioeconomic groups.57 Second, Myriad’s
business plan relies on stringent enforcement of their patent rights,
leaving them the sole provider of an important diagnostic test.58
Myriad’s business practices also caused issues relating to patient
access, treatment, and counseling.59 Third, negative publicity through
advocacy groups framed the debate as patenting human blueprints.60
The ACLU made a tactical decision to attack patentability, rather than
frame this issue in terms of patient health care reform, which would
have addressed patient concerns without implicating long standing
patent law policies.61
A. BRCA1 and BRCA2 Are Important Tools in the Diagnosis of
Breast Cancer and Ovarian Cancer
Breast cancer is the second most common cancer among women
in the United States,62 with approximately one in eight U.S. women
developing breast cancer over her lifetime.63 Breast cancer is one of
the leading causes of cancer death among women of all races and

56. Jon F. Merz & Mildred K. Cho, What Are Gene Patents and Why Are People Worried
About Them?, 8 CMTY. GENETICS 203, 204 (Oct. 2005).
57. See Breast Cancer Statistics, CTRS. FOR DISEASE CONTROL & PREVENTION (Nov. 23,
2010), http://www.cdc.gov/cancer/breast/statistics/.
58. See E. Richard Gold & Julia Carbone, Myriad Genetics: In the Eye of the Policy
Storm, 12 GENETICS IN MED. S39, S41-43 (2010).
59. See id. at S45-48; see also Complaint at 2, Ass’n for Molecular Pathology v. U.S.
Patent & Trademark Office, 702 F. Supp. 2d 181 (S.D.N.Y. 2010) (No. 1:09-cv-04515-RWS),
2009 WL 1343027.
60. See, e.g., Michael Crichton, Op-Ed., Patenting Life, N.Y. TIMES, Feb. 13, 2007, at
A23, available at http://www.nytimes.com/2007/02/13/opinion/13crichton.html; Liberate the
Breach Cancer Genes, supra note 2.
61. See Complaint, supra note 59, at 3.
62. Breast Cancer Statistics, CTRS. FOR DISEASE CONTROL AND PREVENTION (Nov. 23,
2010), http://www.cdc.gov/cancer/breast/statistics/.
63. See Cancer Among Women, CTRS. FOR DISEASE CONTROL AND PREVENTION (Feb.
10, 2011), http://www.cdc.gov/cancer/dcpc/data/women.htm.
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populations in the U.S.64 Per year approximately 202,964 women are
diagnosed with breast cancer and 40,598 women die from it.65
Ovarian cancer is the fifth most common cancer among females in the
U.S. and it is the leading cause of death among reproductive
cancers.66
BRCA1 and BRCA2 are important diagnostic tools in the
treatment of breast cancer and ovarian cancer.67 Estimates place breast
cancer occurrence in a BRCA1 or BRCA2 mutation carrier between
3% and 10%.68 Women with BRCA1 and BRCA2 mutations face up
to an 85% increased risk of developing breast cancer, and up to 50%
increased risk of developing ovarian cancer.69 Therefore, BRCA1 and
BRCA2 diagnostics are important tools in prophylactic treatment for
women with dominantly transmitted BRCA1 and BRCA2
mutations.70 The pervasiveness of breast cancer and ovarian cancer in
the lives of many Americans sets the emotional back-drop for the
debate over control of diagnostic technologies surrounding the
treatment of these diseases.
B. Myriad’s Business Practices
Nearly all of the patented genetic sequences relate to genes
associated with human health, including genes relating to diabetes,
obesity, and cancer.71 The holders of these patents, under U.S. patent
law, are not required to grant licenses on their patent; however, the
majority of these patent holders willingly issue licenses to diagnostic

64. Breast Cancer Statistics, supra note 62.
65. Id.
66. Ovarian Cancer, PUBMED HEALTH (Dec. 28, 2010),
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001891/.
67. See e.g., id.; BRCA1 and BRCA2: Cancer Risk and Genetic Testing, NAT’L CANCER
INST. (May 29, 2009), http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA.
68. Gold & Carbone, supra note 58, at S39.
Of all cases of breast cancer, the estimates of affected women who are carriers of
a mutated allele dominantly transmitted and associated with a high risk of breast
cancer ranges between 5% and 10%. Estimates of breast cancer cases occurring
in BRCA1 or BRCA2 mutation carriers vary from between 3% and 10%.
Id.
69. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d
181, 203 (S.D.N.Y. 2010).
70. See Gold & Carbone, supra note 58, at S39.
71. Olga Bogard, Comment, Patenting the Human Body: The Constitutionality of Gene
Patents and Suggested Remedies for Reform, 63 SMU L. REV. 1319, 1326 (2010).
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laboratories.72 The willing grant of these licenses to diagnostic labs
results in greater access to diagnostic testing, second opinions, price
reductions, and acceptance of insurance providers.73 Myriad,
however, chose an “unprecedented [path] in the field of genetic
testing,” by exercising their legal right to exclude others from using
their invention on the diagnostic tests relating to a predisposition of
breast cancer and ovarian cancer in women.74
Marc Skolnick headed Myriad’s “unprecedented path” into the
successful commercialization of genetic testing. This path began at
the University of Utah’s Center for Genetic Epidemiology, where
Marc Skolnick led a team of researchers who were working to
identify the genetic sequence of BRCA1.75 Skolnick’s work relied on
an extensive database of Mormon families (200,000), which he crossreferenced with a Utah cancer registry that provided him with 40,000
cross-linked entries that “spurred much of Myriad’s future
research”.76
In 1990, Dr. Skolnick concluded additional resources were
needed in order to remain competitive with another team of
researchers who had received a substantial grant from the National
Institute of Health (NIH).77 In 1991, Dr. Skolnick founded Myriad
through a local venture capital group, with the goal of raising the
necessary funding to complete his research.78 Myriad received
significant funding from Eli Lilly and Co.; at least $1 million in
equity and another $1.8 million over three years, the former part of a
$10 million private stock offering.79 Additionally, the NIH
contributed $5 million to the University of Utah research team.80 One
analysis suggested that the NIH contributed one-third of the funding
for the identification of BRCA1.81
Myriad’s business model focused on being the leading

72. Id.
73. Id.
74. Id. at 1327.
75. Gold & Carbone, supra note 58, at S41.
76. Id.
77. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d
181, 201 (S.D.N.Y. 2010).
78. Id.; Gold & Carbone, supra note 58, at S41.
79. Gold & Carbone, supra note 58, at S44.
80. Id.
81. Ass’n for Molecular Pathology, 702 F. Supp. 2d at 202.
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biopharmaceutical diagnostic company.82 Myriad planned to build a
strong and successful relationship with providers, laboratories and
insurers as the go to genetic diagnostic tester.83 They wanted to be
considered a leading market player to be used for future discovered
genetic testing.84 Myriad’s goal was to quickly and effectively
integrate the diagnostic tests into the market, since they were not
subject to FDA clinical trials, in order to generate funds for further
drug discovery.85 Although Myriad’s business model may have
differed from other companies in the health care sector, it was fully
supported by rights granted under patent law.
Myriad marketed several different diagnostic tests.86 The
comprehensive test, which provided the full sequence of both BRCA1
and BRCA2 genes, initially cost $2400.87 “Myriad only offered [their]
testing services through physicians.”88 Myriad relied on genetic
counselors to screen potential test subjects; however, there were not
enough genetic counselors to satisfy market demand and Myriad
ended up having to train and sponsor physicians.89 Myriad did not
require genetic counseling once the patient received the results,
although the hospital was responsible for signing an informed
consent.90
Myriad sent cease and desist letters to other laboratories that
were performing BRCA1 and BRCA2 diagnostic sequencing.91 The
letters specified that the cease and desist notification did not apply to
research testing for non-commercial research programs where the
results were not provided to the patient and where no money was
received in consideration for the test.92 Despite Myriad’s business
plan, Myriad has yet to make a profit from its diagnostic business.93
82. Gold & Carbone, supra note 58, at S42.
83. Id.
84. Id.
85. Id.
86. Id.
87. Id.
88. Id.
89. Id.
90. Id.
91. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp.
2d 181, 187 (S.D.N.Y. 2010).
92. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d
1329, 1340 (Fed. Cir. 2011).
93. Gold & Carbone, supra note 58, at S47.
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C. Both the Negative Publicity Surrounding the Patentability of
Genes and the ACLU’s Complaint, Focused on Patient’s
Access to Diagnostic Tests and Treatments
Publicity fueled the public debate, which characterized Myriad
as owning a patent on a piece of the human body.94 Myriad’s patents
sparked significant newspaper coverage, and the majority of articles
(77.6%) were negative.95 In contrast, only 6.9% were positive and
only around 50% of the news coverage showed more than one
perspective.96 “The story was primarily framed as a social
dilemma”97, as evidenced by the ACLU’s many published articles and
videos.98 The ACLU publications included “Tell Congress: My Genes
Aren’t For Sale” and “Liberate the Breast Cancer Genes.”99 The
ACLU and other patient advocacy organizations focused on the
inability of patients to receive second opinions, access the test, and
the misinformation in the process.100 Even science-fiction author
Michael Crichton in a New York Times opinion piece warned, “You,
or someone you love, may die because of a gene patent that should
never have been granted in the first place.”101
With so many conflicting interests intersecting, the plaintiffs that
filed the complaint in the Southern District of New York were varied
and each asserted their own reasons for standing.102 The plaintiffs can
be categorized into four groups: national organizations, doctors,
patient support and advocacy groups, and individual patients.103
94. See, e.g., Elizabeth Landau, How Human Genes Become Patented, CNN (May 13,
2009),
http://articles.cnn.com/2009-05-13/health/genes.patent.myriad_1_human-genes-brca1trademark-office?_s=PM:HEALTH.
95. Timothy Caulfield et al., Myriad and the mass media: the covering of a gene patent
controversy, 9 GENETICS IN MED. 850, 852 (2007).
96. Id.
97. Id. at 853.
98. See Search Results for Myriad, AM. CIVIL LIBERTIES UNION,
http://www.aclu.org/search/Myriad?type=blog (last visited Sept. 15, 2011).
99. Sandra Fulton, Tell Congress: My Genes Aren’t for Sale, AM. CIVIL LIBERTIES
UNION (Apr. 27, 2010, 4:37 PM), http://www.aclu.org/blog/free-speech-womens-rights/tellcongress-my-genes-arent-sale/; Joel Engardio, Liberate the Breast Cancer Genes, AM. CIVIL
LIBERTIES UNION (May 13, 2009, 8:26 AM), http://www.aclu.org/2009/05/13/liberate-thebreast-cancer-genes/.
100. See Complaint, supra note 59, at 2.
101. Crichton, supra note 60.
102. See Complaint, supra note 59, at 4-13.
103. See id.
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National organizations asserted that they represented members, some
of whom are “ready, willing, and able to engage in research and
clinical practice involving the BRCA1 and BRCA2 genes if the
patents were invalidated.”104 Individual doctors asserted that they
were “ready, willing, and able” to engage in testing or utilize
alternative testing facilities if the patents were invalidated.105 Patient
advocacy groups maintained they would benefit from increased
research and members would benefit from information provided from
multiple laboratory testing.106 Individual female patients complained
of the following issues: Myriad’s denial of MassHealth care
coverage;107 increased research into genetic variants of unknown
significance108; availability of a second opinion which would help
make significant medical decisions; and a need for greater medical
insurance acceptance and affordability.109
IV. THE CLAIMS AT ISSUE IN ASSOCIATION FOR MOLECULAR
PATHOLOGY V. U.S. PATENT AND TRADEMARK OFFICE
There are several types of patent claims on genes. The claims at
issue in Myriad included: composition of matter, diagnostic, and
functional uses.110
A. Composition of Matter
Compositions of matter claims to genetic sequences include the
isolated and purified genetic sequence and all derivative products.111
This type of claim can include the genetic sequence, the virus or
vector containing the claimed sequence, transfected cell lines, and the

104. Id. at 4-5.
105. Id. at 9-10.
106. Id.
107. Id. at 10. Masshealth is Massachusetts’s public health insurance program for low and
medium-income residents. See Massachusetts Health Care Program, MASSRESOURCES.ORG,
http://www.massresources.org/masshealth.html (last visited Feb. 28, 2012).
108. There are many variants of the BRCA1/BRCA2 beyond those, which the Myriad
diagnostic test covered. Some variants of the BRCA1/BRCA2 are still of unknown significance.
For example, Plaintiff Runi Limary received the result “genetic variant of uncertain
significance”. She sought the invalidation of Myriad’s patents in order to access additional
resources for testing and research in order to reveal the significance of her variant gene and its
correlation with cancer. Complaint, supra note 59, at 11.
109. Complaint, supra note 59, at 11.
110. Merz & Cho, supra note 56, at 204.
111. Id. at 205.
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proteins or other therapeutic products associated with the gene.112
The following claims in Patent 5,747,282 (‘282) are illustrative
of the composition of matter claims at issue:
1. An isolated DNA coding for a BRCA1 polypeptide, said
polypeptide having the amino acid sequence set forth in SEQ
ID NO: 2.
2. The isolated DNA of claim 1, wherein said DNA has the
nucleotide sequence set forth in SEQ ID NO:1 . . .
5. An isolated DNA having at least 15 nucleotides of the DNA
of claim 1.
6. An isolated DNA having at least 15 nucleotides of the DNA
of claim 2.113
There are three types of isolated DNA molecules claimed: (1)
isolated sequences identical to naturally occurring genetic sequences
which encompass both the full length gene sequence (Claim 1, ‘282);
(2) shorter isolated DNA strains with as few as fifteen nucleotides
found on the chromosome (Claim 5, ‘282); and (3) cDNA molecules
which differ from the natural gene sequence because the non-coding
sequences are removed and the nucleotide sequence is the
complementary sequence of the naturally occurring RNA (equivalent
to mRNA) (Claim 2, ‘282).114
B. Diagnostic Method Clams
Diagnostic gene patents characterize an individual’s genetic
makeup at a disease-associated location of the individual’s DNA, and
these types of patents cover all known methods of testing for genetic
differences.115 A single gene may have multiple patent applications
claiming different diagnostics of mutations or differences in the

112. Id. at 206.
113. U.S. Patent No. 5,747,282 (filed June 7, 1995).
114. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329,
1364 (Fed. Cir. 2011) (Moore, J., concurring).
115. Merz & Cho, supra note 56, at 204.
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sequence.116 Some diseases are caused by mutations in multiple
genes, therefore creating issues if different companies hold patents on
different diagnostic genetic sequences.117 Additionally, patents can
issue on the same type of diagnostic genetic test, if the same mutation
is responsible for different types of genetic disorders.118 These types
of diagnostic disease patents can monopolize a diagnostic test, since
the patents typically claim all methods of testing for a specific
gene.119
Claim 1 in Patent 5,709,999 (‘999), which looks for mutations in
natural human genes, is illustrative of the diagnostic claims at issue:
1. A method for detecting a germline alteration in a BRCA1 gene,
said alteration selected from the group consisting of the alterations
set forth in Tables 12A, 14, 18 or 19 in a human which comprises
analyzing a sequence of a BRCA1 gene or BRCA1 RNA from a
human sample or analyzing a sequence of BRCA1 cDNA made
from mRNA from said human sample with the proviso that said
germline alteration is not a deletion of 4 nucleotides corresponding
120
to base numbers 4184-4187 of SEQ ID NO:l.

C. Functional Use Method Claims
Claims to the functional use of a gene are based on the discovery
of the role genes play in a certain disease or cellular function.121
Claim 20 in Patent ‘282 is the sole functional use claim at issue:
20. A method for screening potential cancer therapeutics which
comprises: growing a transformed eukaryotic host cell containing
an altered BRCA1 gene causing cancer in the presence of a
compound suspected of being a cancer therapeutic, growing said
transformed eukaryotic host cell in the absence of said compound,
determining the rate of growth of said host cell in the presence of
said compound and the rate of growth of said host cell in the
absence of said compound and comparing the growth rate of said
host cells, wherein a slower rate of growth of said host cell in the
122
presence of said compound is indicative of a cancer therapeutic.

116.
117.
118.
119.
120.
121.
122.

Id.
Id. at 204-205.
Id. at 205.
Id. at 204.
U.S. Patent No. 5,709, 999 (filed Nov. 21, 1991).
See Merz & Cho, supra note 56, at 206.
U.S. Patent No. 5,747,282 (filed June 7, 1995).
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V. JUDGE SWEET’S RULING IN THE S.D.N.Y.
The Association for Molecular Pathology moved for summary
judgment to declare fifteen claims out of seven different patents
issued to Myriad Genetics invalid.123 In Association for Molecular
Pathology, molecular biotechnology and patent law collided,
presenting the question of whether or not isolated human genomic
sequences and their complementary sequences were patentable.124 The
ruling shocked the patent community, because Judge Sweet ruled
against the thousands of patents on genes that the USPTO had issued
over three decades, invalidating both compositions of matter and
method claims as patent ineligible products of nature under 35 U.S.C.
§101.125
In concluding that “DNA represents the physical embodiment of
biological information,” Judge Sweet’s decision emphasized the
similarity between isolated genes and native DNA as a carrier of
information.126 As carriers of information, DNA has unique
characteristics from chemical compounds.127 Chemical compounds
only transmit the information that relates to their own production,
while DNA transmits not only its chemical information, but the
genetics that form a unique human being.128 Based on this reasoning,
genes were held to be products of nature differentiable from other
chemical compounds and therefore unpatentable.129
Judge Sweet invalidated the diagnostic method claims because
they did not specify any other action beyond “analyzing” or
“comparing” two gene sequences to determine if differences
existed.130 Judge Sweet characterized this comparison or analysis of
two different sequences as an unpatentable mental process.131 Judge
Sweet also invalidated the singular functional method claim because

123. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d
181, 184 (S.D.N.Y. 2010).
124. Id. at 185, 198-99.
125. See id. at 238.
126. Id. at 228.
127. Id.
128. Id.
129. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d
181, 228-29 (S.D.N.Y. 2010).
130. Id. at 233-37.
131. Id. at 234.
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it improperly attempted to patent a basic scientific principle.132
VI. COURT OF APPEALS DECISION
On July 29, 2011, the Federal Circuit issued its ruling, with all
three judges writing separately.133
A. Standing
Although the district court found broad standing among all the
plaintiffs, the Federal Circuit spent significant time in finding that
only one plaintiff, Dr. Ostrer, had the necessary standing to maintain
declaratory judgment in the suit.134 Dr. Ostrer had standing based on
the totality of the circumstances: he received a letter from Myriad
proposing a collaborative license requiring N.Y.U. to make payments
to Myriad for each non-research test performed; he was aware that
Myriad was asserting its patent rights against similarly situated
parties; and as a result of litigation he was forced to send all patient
samples to Myriad.135 In addition, Dr. Ostrer maintained he could
have proceeded with testing without taking a license due to his belief
that the patents are invalid, he intended to undertake BRCA1 testing,
and stated unequivocally that he would immediately begin such
testing if the patents were ruled invalid.136 Furthermore, “Myriad’s
challenged composition and method claims undisputedly provide[d]
‘an absolute barrier’ to Dr. Ostrer’s ability to undertake BRCA
diagnostic testing activities, and a declaration of those claims’
invalidity would remove that barrier.”137 The other plaintiffs—
patients, advocacy groups, national organizations, and medical
organizations—failed to articulate an adverse legal controversy.138
Judge Lourie held that “[s]imply disagreeing with the existence of a
patent or even suffering an attenuated, non-proximate, effect from the
existence of a patent” is not enough to establish standing for
132. Id. at 237 (“The recited transformative steps . . . represent nothing more than
preparatory, data-gathering steps to obtain growth rate information and not render the claimed
mental process patentable under §101.”).
133. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329,
1333 (Fed. Cir. 2011).
134. Id. at 1344.
135. Id. at 1345.
136. Id. at 1345-46.
137. Id. at 1348.
138. Id.
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declaratory judgment.139
B. Method Claims
The district court’s decision predated Bilski’s rejection of the
machine-or-transformation test as the exclusive test for determining a
patent eligible process.140 In light of Bilski, Judge Lourie determined
all the diagnostic method claims were directed to patent-ineligible
abstract mental processes and therefore fail the machine-ortransformation test.141
Myriad’s diagnostic method claims that “compare” or “analyze”
two gene sequences fell outside the scope of §101.142 The claims
recite “nothing more than the abstract mental steps necessary to
compare two different nucleotide sequences.”143 Myriad’s claims did
not include a step where the BRCA gene sequence must first be
“determined.”144 In contrast, Myriad’s method claims to potential
cancer therapeutics were determined to be a patent-eligible process
because they included the step of “determining” the cells’ growth
rates, which necessarily involves physical manipulation of the cells
and are central to the purpose of the claim.145
C. Composition of Matter Claims: Isolated DNA Molecules
Judge Lourie summarized the debate over the patentability of
isolated DNA molecules as a disagreement “on whether and to what
degree such molecules fall within the exception for products of
nature.”146 The disagreement on whether and what degree such
molecules qualify as an exception to patentable subject matter
permeated all three different Federal Circuit judicial opinions as
well.147

139.
140.
141.
142.
143.
144.
145.
146.
147.

Id.
Id. at 1355.
Id.
Id.
Id. at 1356.
Id. at 1357.
Id.
Id. at 1350.
See generally id.
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1. Majority Opinion, Judge Lourie
Judge Lourie, in applying the Chakrabarty-Funk Brothers
“markedly different” framework, held that isolated DNA molecules
are markedly different due to their distinctive chemical identity and
nature from molecules that exist in nature.148 Judge Lourie stressed
that chemical covalent bonds must be broken in order to form an
isolated DNA segment and that isolated DNA segments can be
independently synthesized.149 Judge Lourie distinguished isolated
DNA molecules from purification, describing purification as a
process resulting in an identical molecule in pure form.150 Judge
Lourie suggested DNA is not purified in its isolated form, because
isolated genetic sequences do not exist within a physical mixture from
which it can be purified—they must be chemically cleaved from their
chemical composition with other genetic material.151
Judge Lourie also indicated that Judge Sweet wrongly
determined patentability based on DNA’s genetic function—
transformation of information—rather than what it is: a distinct
chemical entity.152 The majority opinion emphasized deference to the
legislature and long-standing USPTO practice.153 Judge Lourie noted
that the Supreme Court has “more than once cautioned that courts
‘should not read into the patent laws limitations and conditions which

148.

Id. at 1351.
Native DNA exits in the body as one of forty-six large, contiguous DNA
molecules. Each DNA molecule is itself an integral part of a larger structural
complex, a chromosome. In each chromosome the DNA molecule is packaged
around histone proteins into a structure called chromatin, which in turn is
packaged into the chromosomal structure. Isolated DNA, in contrast, is a free
standing portion of a native DNA molecule, frequently a single gene. Isolated
DNA has been cleaved (i.e., had covalent bonds in its backbone chemically
severed) or synthesized to consist of just a fraction of a naturally occurring DNA
molecule.

Id.
149. Id. at 1352-1353.
150. Id. at 1352.
151. Id.
152. Id. at 1353 (“Uses of chemical substances may be relevant to the non-obviousness of
these substances or to method claims embodying those uses but the patent eligibility of an
isolated DNA is not negated because it has similar informational properties to a different more
complex natural material that embodies it.”).
153. Id. at 1354-55 (Because of the thousands of genetic patents and longstanding USPTO
practice of granting these type of patents, Judge Lourie noted that a categorical exclusion to
patentable subject matter should come from Congress and not the Judiciary).
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the legislature has not expressed.’”154
2. Concurring Opinion, Judge Moore
In his concurring opinion, Judge Moore emphasized that he did
not believe that the different chemical structure emphasized by Judge
Lourie rendered the isolated DNA per se patentable.155 Judge Moore
also suggested that an isolated genetic sequence is not per se
unpatentable as a law of nature, as Judge Sweet held, given the
chemical differences highlighted by Judge Lourie.156 Judge Moore
framed the issue as whether the chemical differences in the isolated
genetic sequences impart a new utility, which makes the molecule
markedly different than they occur in nature.157
Judge Moore easily found claims to shorter isolated genetic
molecules patentable, because they can be used as primers in
diagnostic screening processes to detect gene mutations, or as probes
with isolated radiolabeled sequences mirroring those on the
chromosome.158 In contrast, naturally occurring DNA cannot be used
to accomplish either of these two functions.159 Judge Moore found
longer strands of isolated DNA presented a “closer case” than shorter
isolated DNA strands.160 A fully sequenced isolated gene maintains
the same chemical differences as a shorter strand of isolated DNA;
however, it is too long to be used as a probe and is unsuitable as a
primer; therefore, larger strands of isolated DNA do not enlarge the
range of utility.161 Judge Moore found that the settled expectations of
154.
155.
156.
157.
158.

Id. at 1353.
Id. at 1364-65 (Moore, J., concurring in part).
Id. at 1365.
Id.
See id.
The ability to use isolated DNA molecules as the basis for diagnostic genetic
testing is clearly an “enlargement of the range of . . . utility” as compared to
nature. . . . Because the different chemical structure of the isolated DNA, which
is a product of the intervention of man, leads to a different and beneficial utility, I
believe small, isolated DNA fragments are patentable subject matter. . . . Man has
whittled the chromosomal DNA molecule down to a 15 nucleotide sequence—
defining the parts to be retained and discarded. And the result is a product with a
function (primer or probe) that is entirely different from the full gene from which
it was obtained.

Id.
159.
160.
161.

Id.
Id. at 1366.
See id.

18 JACOB (DO NOT DELETE)

2012]

3/28/2012 12:14 PM

SHOULD GENES BE PART OF PATENT BARGAIN

423

patent law “tip the scale in favor of patentability.”162
3. Dissenting Opinion, Judge Bryson
Judge Bryson held that isolated genetic sequences are
categorically unpatentable as composition of matter claims.163 Judge
Bryson framed the issue as whether an inventor could obtain a patent
on a human gene.164 The dissent compared the isolated genetic
sequences to minerals that are hard to extract from a natural setting,
and compared the cleaving of a covalent bond to the cleaning of a
diamond with water or solvent to remove dirt or grime.165 Judge
Bryson’s reasoning was similar to Judge Sweet’s reasoning in the
district court opinion. Judge Bryson based his holding on the belief
that the structural differences are irrelevant because the function of
the genetic sequence is the same as the native DNA—both transfer
information, whether it is being used in the body to code a protein or
used as a primer or a probe in diagnostic technologies.166
Judge Bryson characterized the majority opinion’s deference to
past precedent as adverse possession in patent law.167 To counter the
majority’s reliance on USPTO precedent and deference to the
legislature, Judge Bryson further justified his stance based on the
following: the ruling in Chakrabarty that rendered microorganisms
patentable in the face of USPTO policy that microorganisms were not
patentable, the USPTO’s lack of rule-making authority, and the
Department of Justice’s Opinion on behalf of the United States.168
Judge Bryson additionally cited policy arguments relating to the
preemptive force of these patents resulting in a biotechnology
“anticommons” as a reason against patentability.169

162. Id. at 1367.
163. See id. at 1373-74 (Bryson, J., concurring in part and dissenting in part).
164. Id. at 1373.
165. See id. at 1375.
166. See id. at 1378 (The identity is key to its value. If it were altered in any meaningful
way it could not be used for its diagnostic value).
167. See id. at 1381.
168. Id. at 1380-81.
169. See id. at 1379-80.
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VII.WHAT NOW? LOOKING PAST THE COURT OF APPEALS DECISION
Both parties petitioned the Federal Circuit for rehearing. 170 The
Association for Molecular Pathology moved for rehearing based on
the claims to the isolated genetic sequences and an error in the
determination of standing.171 Myriad’s petition for rehearing focused
only on standing and urged the Federal Circuit to dismiss the case as
moot based on Dr. Ostrer’s departure from N.Y.U.172 Interestingly,
while Myriad asked to dismiss the case as moot, they did not ask to
vacate the judgment,173 likely because the judgment was mostly
favorable to them in the assurance of the validity of genetic
sequences. Additionally, Myriad did not ask for a rehearing on the
diagnostic claims.174 However, the Federal Circuit denied both
petitions for rehearing.175 While the plaintiffs have filed a petition for
review in front of the Supreme Court,176 even if review is granted, the
outcome is uncertain for the following reasons.
A. Standing
By the time this case reaches a Supreme Court appeal, the parties
may no longer have standing. Dr. Ostrer has left N.Y.U. and is
currently at the Department of Genetics at Albert Einstein College of
Medicine,177 which does not have the ability to perform clinical
genetic testing.178 The requirement to maintain standing continues
throughout the appellate process.179 Dr. Ostrer no longer has the

170. See generally Plaintiffs-Appellees’ Petition for Panel Rehearing, supra note 9;
Defendants-Appellants’ Petition for Panel Rehearing, supra note 9.
171. See Plaintiffs-Appellees’ Petition for Panel Rehearing, supra note 9, at 1, 11.
172. See Defendants-Appellants’ Petition for Panel Rehearing, supra note 9, at 1.
173. See id. at 9-11.
174. See generally id.
175. See Disposition Sheet, U.S. CT. OF APPEALS FOR THE FED. CIR. (Sept. 12, 2011),
http://www.cafc.uscourts.gov/images/stories/disposition/daily.pdf (last visited Sept. 17, 2011).
176. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329,
1367 (Fed. Cir. 2011), petition for cert filed, (U.S. Dec. 07, 2011) (No. 11-725).
177. See Faculty Profile for Harry Ostrer, M.D., ALBERT EINSTEIN C. OF MED.,
http://www.einstein.yu.edu/home/faculty/profile.asp?id=12751&k (last visited Feb. 29, 2012).
178. Letter from Gregory A. Castanias, Attorney for Defendants-Appellants, to Mr. Jan
Horbaly, Clerk at the U.S. Ct. of Appeals for the Fed. Cir. 1 (July 27, 2011), available at
http://inventivestep.files.wordpress.com/2011/07/myriadletter1.pdf
[hereinafter
Castanias
Letter].
179. See Lewis v. Cont’l Bank Corp., 494 U.S. 472, 477-78 (1990).
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ability to immediately resume testing, which would likely extinguish
his standing.180
It is unlikely that the Supreme Court would apply the district
court’s broad finding of standing to the other plaintiffs. Judge Sweet’s
sweeping finding of standing was a dangerous test that does not align
with patent law. Judge Lourie was correct in his reasoning that
“[s]imply disagreeing with the existence of a patent or even suffering
an attenuated, non-proximate, effect from the existence of a patent
does not meet the Supreme Court’s requirement for an adverse legal
controversy or sufficient immediacy and reality to warrant the
issuance of a declaratory judgment.”181 Allowing a broad base of
people, in this case patients, to litigate the validity of patents would
open the floodgates of litigation. Ex parte re-examinations already
allow third parties to question the validity of patents. Patent holders
are granted a twenty-year monopoly for their investment and
disclosure of their technology to the public knowledge base. A
twenty-year monopoly will inevitably harm consumers of the product
in some general way, but giving them standing does not create a
remedy for the injury. It only serves to weaken the patent system.
B. Composition of Matter Claims
As evidenced by the separately written judicial opinions, the
divide between both scientific and legal minds in dozens of amicus
briefs,182 and disagreement even within the branches of

180. See Castanias Letter, supra note 177, at 2.
181. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329,
1348 (Fed. Cir. 2011).
182. Compare, e.g., Brief for AARP as Amicus Curiae in Support of Plaintiffs-Appellees
and Arguing for Affirmance at 2-4, Ass’n for Molecular Pathology v. U.S. Patent & Trademark
Office, 653 F.3d 1329 (Fed. Cir. 2011) (No. 2010-1406), 2011 WL 585711 (arguing that DNA
and human genes are unpatentable under 35 U.S.C. §101 and the patents should be declared
unenforceable, because public health necessitates their invalidation); Brief for the S. Baptist
Convention as Amicus Curiae in Support of Plaintiffs-Appellees and Arguing for Affirmance at
2, Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir.
2011) (No. 2010-1406), 2011 WL 585712 (arguing that gene sequence patents are unpatentable
subject matter and are harmful to individuals no matter what their religious beliefs); Brief of
Amici Curiae E. Richard Gold et al. in Support of Appellees and Affirmance at 26, Ass’n for
Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011) (No.
2010-1406), 2010 WL 5558511 (arguing that the genetic sequence contained in DNA should be
considered as information, and should therefore be excluded as unpatentable abstract subject
matter unless the claim has a specific function), with, e.g., Brief of Amici Curiae Rosetta
Genomics, Ltd. et al. in Support of Defendants-Appellants, Supporting Reversal at 14-28, Ass’n
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government,183 reasonable people differ on how science and patent
law should align. Opinions on the patentability of genes vary not so
much because of the legal analysis, but because of the strong
emotions behind the issue. While both the majority and concurring
opinions in the Federal Circuit found that public policy fell on the
side of deference to long-held property rights, Judge Bryson’s
dissenting opinion emphasized that his view of public policy
outweighed that deference.184 Therefore, the view on how patent law
should be applied to science is inextricably intertwined with policy.
In Chakrabarty, the Supreme Court faced a similarly divisive
issue.185 Chakrabarty, like Myriad, presented the judiciary with a
“gruesome parade of horribles” in several amicus briefs in support of
the plaintiff’s argument against the patentability of genetic

for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011)
(No. 2010-1406), 2010 WL 4853324 (arguing that isolated DNA is patentable subject matter,
and patents stimulate innovation).
183. See, e.g., Brief for the U.S. as Amicus Curiae in Support of Neither Party at 9-11,
Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir.
2011) (No. 2010-1406), 2010 WL 4853320; Heidi Ledford, Has the US Government Abandoned
Gene Patents?, NATURE.COM NEWSBLOG (Nov. 1, 2010),
http://blogs.nature.com/news/2010/11/will_the_us_government_abandon.html (“[N]o lawyers
from the patent office are listed on the brief – a possible sign that the position has few fans at the
USPTO, which has granted thousands of gene patents over the years.”); David Kappos, Under
Sec’y of Commerce for Intellectual Prop., Building Bridges and Making Connections Across the
IP System, Speech at the George Washington Law Symposium 3 (May 11, 2010), in
USPTO.GOV, available at
http://www.uspto.gov/news/speeches/2010/Kappos_GW_Law_Symposium.jsp.
This has a potentially enormous impact on the bio industry. The USPTO has
issued more than 20,000 patents claiming isolated DNA molecules, almost 4,000
of which directly claim isolated human DNAs encoding a protein. The USPTO
has also issued tens of thousands of patents on other types of isolated and
purified chemicals, all of which could be put at risk by the District Court’s
decision. The USPTO has for decades issued patents covering isolated and
purified DNA on the scientific basis that an isolated snippet of DNA does not
“exist” in nature in the way it is claimed in patents, because naturally occurring
DNA must be isolated—that is, separated from the surrounding biological
material—and purified. Your body does not contain isolated DNA. Isolated DNA
simply is not found in nature.
Id.
184. Ass’n for Molecular Pathology, 653 F.3d at 1373 (Bryson, J., concurring in part and
dissenting in part) (“In my view, those claims are not directed to patentable subject matter, and
if sustained the court’s decision will likely have broad consequences, such as preempting
methods for whole-genome sequencing, even through Myriad’s contribution to the field is not
remotely consonant with such effects.”).
185. See Diamond v. Chakrabarty, 447 U.S. 303, 307 (1980).
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inventions.186 The court noted that “[t]hese arguments are forcefully,
even passionately, presented; they remind us that, at times, human
ingenuity seems unable to control fully the forces it creates—that,
with Hamlet, it is sometimes better ‘to bear those ills we have than fly
to others that we know not of.’”187 The Supreme Court strongly
emphasized that Congress, and not the Court, should decide
categories of statutory exclusion, especially when based on public
policy:
What is more important is that we are without competence to
entertain these arguments—either to brush them aside as fantasies
generated by fear of the unknown, or to act on them. The choice
we are urged to make is a matter of high policy for resolution
within the legislative process after the kind of investigation,
examination, and study that legislative bodies can provide and
courts cannot. That process involves the balancing of competing
values and interests, which in our democratic system is the
business of elected representatives. Whatever their validity, the
contentions now pressed on us should be addressed to the political
branches of the Government, the Congress and the Executive, and
188
not to the courts.

Chakrabarty is dispositive. If a categorical statutory exclusion to
genetic patents is created, dislodging long-held property rights, the
decision should be made by Congress and not the judiciary.
“Congress is free to amend §101 so as to exclude from patent
protection” genetic sequences under the product of nature exception,
“[o]r it may choose to craft a statute specifically designed” to address
them.189 Until Congress takes such actions, the Court must strictly
construe the language of §101 as it currently exists.190
In his dissent, Judge Bryson used Chakrabarty as an affirmation
that the Supreme Court does not owe deference to past patent law
policy, because the Court created a new category of patent protection
in microorganisms.191 However, interpreting a statute as granting a

186. Id. at 316.
187. Id.
188. Id. at 317.
189. Id. at 318.
190. Id. at 318 (“Our task, rather, is the narrow one of determining what Congress meant
by the words it used in the statute; once that is done our powers are exhausted.”).
191. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329,
1381 (Fed. Cir. 2011) (Bryson, J., concurring in part and dissenting in part) (“Finally, prior to
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property right where none existed before is much different than taking
away a property right that has existed for thirty years resulting in the
grant of thousands of patents without significant congressional action.
Traditionally, Congress does not need to authorize the patentability of
new fields of inventions, since breakthrough innovations often stretch
beyond the boundaries of science.192 In contrast, an invention that has
been around for decades provides Congress with ample opportunity to
create legislation if they do not wish that type of invention to be a part
of the patent bargain. Congress does not need to explicitly authorize
inventions, but once an invention has been deemed patent eligible and
Congress has not acted to prevent the issuance of thousands of patents
over several decades, the judiciary should not arbitrarily overturn the
long-standing property right.
Judge Bryson incorrectly suggested that the executive’s
Department of Justice brief in support of neither party indicated that
the patent office has changed their stance on genetic sequence
patents.193 On May 11, 2010, the director of the USPTO, David
Kappos, said in a speech to the George Washington Law Symposium:
The USPTO has for decades issued patents covering isolated and
purified DNA on the scientific basis that an isolated snippet of
DNA does not “exist” in nature in the way it is claimed in patents,
because naturally occurring DNA must be isolated—that is,
separated from the surrounding biological material—and purified.
Your body does not contain isolated DNA. Isolated DNA simply is
not found in nature. . . . It has been the view of the USPTO that the
purified version of a naturally occurring compound—where the
purified version does not exist in nature—is eligible for patent
194
protection.

On November 1, 2010, David Kappos reaffirmed that view point
even in light of the Department of Justice’s brief, and told the DOW
Jones news service: “The USPTO at the present time is maintaining
the Supreme Court’s decision in Chakrabarty, the PTO had determined that microorganisms
were not subject to patenting, but the Supreme Court gave no indication that it regarded that
view as entitled to deference.”).
192. See Chakrabarty, 447 U.S. at 316 (“A rule that unanticipated inventions are without
protection would conflict with the core concept of the patent law that anticipation undermines
patentability. . . . Congress employed broad general language in drafting § 101 precisely because
such inventions are often unforeseeable.”).
193. See Ass’n for Molecular Pathology, 653 F.3d at 1380-81 (Bryson, J., concurring in
part and dissenting in part).
194. Kappos, supra note 182, at 3-4.
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the status quo. We’re continuing with current procedures as they
are.”195 Clearly, the Department of Justice’s brief did little to dictate
USPTO policy on genetic sequences.
Accordingly, the Supreme Court should interpret 35 U.S.C. §101
through strict interpretation, apply it to the science, and rightly defer
the public policy arguments to Congress. It is unlikely that the
Supreme Court would declare all patents to genetic sequences as
categorically unpatentable as a product of nature. It is incorrect to
focus solely on the similarity between isolated DNA and native DNA
as an informational carrier, rather than the differences. Chakrabarty
clearly states that the applicable test does not focus on the similarities,
but whether the non-naturally occurring composition of matter was a
product of human ingenuity with “distinctive name, character [and]
use.”196 The compositions of matter claims in fact do not claim the
raw information of the genetic sequence of BRCA1 and BRCA2.197
The claim is an isolated man-made DNA molecule with an amino
acid sequence that carries the raw information of the genetic
sequence. It is the molecule that is claimed, not the information. In
other words, the molecule would not exist but for man’s intervention.
Under a strict interpretation of §101, a composition of matter
claim to an isolated genetic sequence is patent eligible because it is a
product of human ingenuity, non-naturally occurring, and has a
distinctive character, name and use. In this case, the claimed sequence
could be used as primer and probe in the detection of genetic
abnormalities, and native DNA could not. “Isolated DNA” does not
exist in nature, and isolation often tips the scales to patentability.198
Although larger sequences of isolated genetic sequences may not
have the practicality of primer or probe, policy weighs in their favor
as Judge Moore outlined in her concurring opinion,199 and they are
still man-made molecules with a distinct chemical composition that

195. Gene Quinn, Conflicting Positions on Gene Patents in Obama Administration, IP
WATCHDOG (Nov. 2, 2010, 2:27 PM), http://ipwatchdog.com/2010/11/02/conflicting-positionson-gene-patents-in-obama-administration/id=13085/.
196. Chakrabarty, 447 U.S. at 309-10 (alteration in original) (quoting Hartranft v.
Wiegmann, 121 U.S. 609, 615 (1887)).
197. See generally U.S. Patent No. 5,747,282 (filed June 7, 1995).
198. See Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95, 103 (C.C.S.D.N.Y. 1911),
aff’d in part, rev’d in part, 196 F. 496 (2d Cir. 1912).
199. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d
1329, 1366-67 (Fed. Cir. 2011) (Moore, J., concurring in part).
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do not occur in nature.200 The Supreme Court should not overturn
decades of recognized property rights through a categorical exclusion
of genetic sequences as “products of nature”—the Court will rightly
defer the policy arguments to Congress.
C. The Diagnostic Method Claims
Less than a year prior to the Myriad decision, Judge Lourie ruled
on a similar diagnostic method claim in Prometheus.201 The following
method claim was representative of the claims at issue in Prometheus:
1. A method of optimizing therapeutic efficacy for treatment of
an immune-mediated gastrointestinal disorder, comprising:
(a) administering a drug providing 6–thioguanine to a
subject having said immune-mediated gastrointestinal
disorder; and
(b) determining the level of 6–thioguanine in said subject
having said immune-mediated gastrointestinal disorder,
wherein the level of 6–thioguanine less than about 230 pmol
per 8x108 red blood cells indicates a need to increase
the amount of said drug subsequently administered to
said subject and
wherein the level of 6–thioguanine greater than about 400
pmol per 8x108 red blood cells indicates a need to
decrease the amount of said drug subsequently
administered to said subject.202
This claim essentially covers administration of a drug, a
determination of a corresponding natural correlation in the human
body based on that drug, and the result of that determination being
compared to a predetermined amount. Judge Lourie held that the

200. See Ass’n for Molecular Pathology, 653 F.3d at 1351-52; Kappos, supra note 182, at
4 (“It has been the view of the USPTO that the purified version of a naturally occurring
compound—where the purified version does not exist in nature—is eligible for patent
protection.”).
201. See Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347, 1349 (Fed.
Cir. 2010), cert. granted, 131 S. Ct. 3027 (June 20, 2011).
202. Id. at 1350.
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administering and determining steps were both transformative and
central to the claims; therefore, Judge Lourie held the claim to be
valid.203
When Myriad is read in correspondence with Prometheus, the
differentiation between method claims written without a
“determining” step and claims written with a “determining” step is
slim.204 Myriad argued that steps of extracting a human DNA sample
and sequencing the BRCA molecule from that human DNA sample
necessarily preceded the comparing step, and should be read into the
claim.205 However, Judge Lourie interpreted the claims as only
comparison between two sequences “accomplished by mere
inspection alone.”206 If the diagnostic method claims in Myriad had a
step in which the determining of the genetic sequence was obtained
through the use of an isolated genetic sequence, Judge Lourie likely
would have upheld these claims as patent eligible based on his
holding in Prometheus. Judge Lourie’s distinction between the
method claims in Prometheus and the method claims in Myriad is
mere semantics. If this narrow distinction is upheld, it will do little
more than alter the way in which diagnostic method claims are
drafted.
The Supreme Court appears to be positioning itself for a ruling
on biomedical method claims in the near future. In 2006, the Supreme
Court granted, and then dismissed as “improvidently granted,” review
to Labcorp v. Metabolite.207 With no majority opinion, Justice Breyer,
joined by Justice Stevens and Justice Souter, wrote a dissenting
opinion.208 The claims, which were determined to be valid in the

203. Id. at 1357, 1359.
204. See, e.g., U.S. Patent No. 5,709,999 col. 161 17-25 (filed Nov. 21, 1991).
Claim 1:
A method for detecting a germline alteration in a BRCA1 gene, said alteration
selected from the group consisting of the alterations set forth in Tables 12A, 14,
18 or 19 in a human which comprises analyzing a sequence of a BRCA1 gene or
BRCA1 RNA from a human sample or analyzing a sequence of BRCA1 cDNA
made from mRNA from said human sample with the proviso that said germline
alteration is not a deletion of 4 nucleotides corresponding to base numbers 41844187 of SEQ ID NO:l.
Id.
205. See Ass’n for Molecular Pathology, 653 F.3d at 1356.
206. Id. at 1357.
207. Labcorp v. Metabolite Labs., Inc., 548 U.S. 124, 125 (2006) (per curiam).
208. Id.
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lower courts, were directed to a process of measuring the level of an
amino acid and human body fluid and noticing whether the level was
elevated above the normal level in order to detect vitamin
deficiency.209 Justice Breyer argued that a correlation between
homocysteine and vitamin deficiency was a correlation that falls
under the “natural phenomenon” exception to section 101
patentability, which cannot be avoided by an instruction to perform
the process of reading numbers in light of medical knowledge.210
The Supreme Court has granted review of Prometheus and will
likely issue a ruling this fall.211 Based on the Supreme Court’s grant
of review in Prometheus, Justice Breyer’s dissent in Labcorp v.
Metabolite, and the Court of Appeals holding in Association for
Molecular Pathology, diagnostic method claims comparing a “natural
correlation” are at the forefront of the biotechnology battle. The
Supreme Court’s future ruling in Prometheus may dictate how the
Court will proceed in biotechnology cases, and will determine how
the Court will proceed in Association for Molecular Pathology at least
in regards to the method claims at issue.
Prometheus, Labcorp, and Association for Molecular Pathology
highlight why patent law in biotechnology should not be bulldozed in
order to attempt to address patient needs that are tangentially affected
through patent law. All of these cases touch on diagnostic
technologies. Of these three cases, only Myriad’s claims related to
genetic diagnostics. Therefore, even if Myriad’s patents were struck
down, the issues faced by the patients seeking treatment through all
types of diagnostic technologies would not benefit from their
invalidation. Notably, the method claims in Myriad were found
unpatentable not because they were a natural phenomenon, but
because they were an abstract mental process.212 This distinction will
not create a bar to patenting diagnostic biotechnology tests that use
natural phenomenon like metabolite correlations, genetic sequences,
or chemical responses as long as they do not claim only an abstract
mental process and satisfy Bilski’s “useful and important clue” of the
209. Id.
210. Id. at 134, 137.
211. See Docket for No. 10-1150, SUPREME CT. OF THE UNITED STATES,
http://www.supremecourt.gov/Search.aspx?FileName=/docketfiles/10-1150.htm (last visited
Oct. 7, 2011).
212. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d
1329, 1355 (Fed. Cir. 2011).
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machine or transformation test.213
Fundamentally, the issues presented in Myriad circulate around
better patient care. Therefore, weakening patent protection at best
provides an ineffective piecemeal approach of targeting limited issues
in patient service. Biotechnology research is extremely expensive, and
weakening patents in this sector only serves to disincentivize much
needed private funding into medical technologies. Invalidation of
Myriad’s patent would be extremely limited in its scope and effect.214
This is a broad issue, and should therefore be addressed in a manner
that would actually address the needs of patients.
VIII.POLICY CONSIDERATIONS AND POSSIBLE SOLUTIONS
In April 2010, the Secretary of Health and Human Service’s
advisory committee on genetics, health, and society (SACGHS) wrote
a report in conjunction with NIH on Gene Patents and Licensing
Practices and Their Impact on Patient Access to Genetic Tests. 215
Because it was unclear how a congressional ban on genetic sequences
would affect other biotechnologies including therapeutic uses of
genes, SACGHS concluded that it was prudent to narrowly tailor any
solution “to improve genetic test development and patient access
without affecting patent rights in other areas.”216 The Committee,
therefore, did not recommend a congressional ban on genetic
sequences.217
Recently, Congress and the Executive Branch took a narrow
approach to patents on genetic sequences. President Obama signed
into law the America Invents Act on September 16, 2011.218 Section

213.
214.

See Bilski v. Kappos, 130 S.Ct. 3218, 3227 (2010).
See U.S. DEPT. OF HEALTH & HUMAN SERVS., GENE PATENTS AND LICENSING
PRACTICES AND THEIR IMPACT ON PATIENT ACCESS TO GENETIC TESTS: REPORT OF THE
SECRETARY’S ADVISORY COMMITTEE ON GENETICS, HEALTH, AND SOCIETY 92 (2010)
[hereinafter SACGHS REPORT] , available at
http://oba.od.nih.gov/oba/sacghs/reports/SACGHS_patents_report_2010.pdf (“Furthermore,
even if the plaintiffs prevail, this would not lead to the automatic invalidation of all existing
patents on genes and associations.”).
215. See generally id.
216. Id. at 91-92.
217. Id.
218. Leahy-Smith America Invents Act, Pub. L. No. 112-29, § 27(a), 125 Stat. 283, 338
(2011) (to be codified in scattered sections of 35 U.S.C.), available at
http://www.gpo.gov/fdsys/pkg/PLAW-112publ29/pdf/PLAW-112publ29.pdf. See also Press
Release, The White House, President Obama Signs America Invents Act, Overhauling the
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27 specifies that the “Director [of the USPTO] shall conduct a study
on effective ways to provide independent, confirming genetic
diagnostic test activity where gene patents and exclusive licensing for
primary genetic diagnostic tests exist.”219 Notably, the study calls for
research into second opinions on diagnostic tests and nothing more.
The report is due no later than 9 months after the enactment of the
Act.220 This is an extremely narrow provision in an act with lengthy
patent reform. If Congress had wanted to create an exception to
genetic sequence patentability they could have done so while passing
this act.
Proponents of invalidating genetic patents cite several policy
concerns in support of their contention that patent claims to genetic
sequences “cause more harm than good to society and technological
development.”221 There are three general categories of concern:
preemption of future research; quality of care and patient access; and
an unearned extended patent monopoly. Most of these concerns are
misplaced, and in fact, would not be well addressed by creating a
broad exception to section 101 patentability.
A. Weakening Patent Rights in Biotechnology Would Both
Negatively Impact Private Investment and Create
Uncertainty in the Protection of Other Biotechnology
Property Rights
Scientific research and development of life-saving technologies
is expensive and private investment and competition significantly
contributes to the efficient development of new technologies;
however, investment in private research will not continue if there is
no reward. In 2009, BIO (Biotechnology Industry Organization)
conducted a survey of 150 biotechnology companies.222 The survey
found that half of the companies were founded on the basis of

Patent System to Stimulate Economic Growth, and Announces New Steps to Help Entrepreneurs
Create Jobs (Sept. 16, 2011), available at http://www.whitehouse.gov/the-pressoffice/2011/09/16/president-obama-signs-america-invents-act-overhauling-patent-system-stim.
219. Leahy-Smith America Invents Act § 27(a).
220. See Leahy-Smith America Invents Act § 27(d).
221. See Mary Mitchell & Dana A. Remus, Commentary, Interstitial Exclusivities After
Association for Molecular Pathology, 109 MICH. L. REV. FIRST IMPRESSIONS 34, 34-35 (2010),
available at http://www.michiganlawreview.org/assets/fi/109/mitchellremus.pdf.
222. See BIO 2009 Member Survey, BIOTECHNOLOGY INDUSTRY ORGANIZATION, 1
(2009), http://www3.bio.org/ecs/bd/TechTransfer_Survey_Summary_Conclusions.pdf.
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obtaining a licensing agreement and that the majority of companies
with no marketed product expected to spend five to fifteen years
developing the product.223 In the House of Representatives hearing on
Gene Patents and Other Genomics, Dennis Henner from Genentech,
Inc., testified that his company invests about $400 million a year in
the research and development of therapeutic products focusing on the
identification of human proteins.224
The grant of a patent, in part, recognizes the investment that an
individual or company assignment has spent in development of a new
invention. The patent serves as a reward for the investment and risk
associated with high-priced technologies, especially in the realm of
biotechnology.225 Although the United States government funds most
basic research (59%), the private business sector accounts for the
largest share of research and development, hovering between 69-75%
of total research and development funding.226
Basic research does not bring medical diagnostic technology to
the market for patient care, and private industry is the largest
contributor of funds to applied research and development.227
Scientists searching for gene-disease associations cannot perform the
needed research without significant capital and resources.228 Funding
for meaningful gene-disease associations are confirmed only when the
basic research discoveries are followed by large amounts of
replication and validation, which is often cost prohibitive.229 The
research team that founded Myriad received $5 million in funding in
1993 after the formation of the company.230 However, this paled in
comparison to the $10 million in private stock, along with millions in

223. See id.
224. Gene Patents and Other Genomic Inventions: Hearing Before the Subcomm. on
Courts & Intellectual Prop. of the H. Comm. on the Judiciary, 106th Cong. 55 (2000) (statement
of Dennis J. Henner, Ph.D., Senior Vice President, Research, Genentech, Inc.).
225. See generally Science and Engineering Indicators 2008: Chapter 4. Research and
Development: National Trends and International Linkages, NAT’L SCI. BD. (2008),
http://www.nsf.gov/statistics/seind08/pdf/c04.pdf.
226. See id. at 4-5.
227. See Research and Development: Essential Foundation for U.S. Competitiveness in a
Global Economy, NAT’L SCI. BD. (2008), http://www.nsf.gov/statistics/nsb0803/start.htm
(“[i]ndustrial contributions to national R&D now far outpace Federal R&D support . . . .” Most
industrial contributions support applied R&D and not basic R&D.).
228. See SACGHS REPORT, supra note 213, at 23.
229. See id.
230. See Gold & Carbone, supra note 58, at S41.
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equity from Eli Lilly, a private pharmaceutical company.231 Myriad
has yet to make a profit on the investment it made into the research
and development of its product.232
On a profit-based research model, a limited patent monopoly
provides the incentive to investors to take the risk in biotechnology.
Investors in biotechnology believe that in order to succeed in their
investment there must be strong, enforceable patents, and any
perception that patent reform might weaken that patent protection will
adversely impact the availability of biotechnology funding.233
Biotechnology companies without a successful product on the market
must rely substantially on the availability of investment funding to
survive.234 In 2000, when Prime Minister Tony Blair and President
Bill Clinton issued a “bland” statement urging public access to raw
DNA sequencing information, many biotech companies lost as much
as 20% of their value.235
Private investors that are providing the funding for research and
development look at patents as a protection of their investment.236
Myriad’s research into the genetic sequences associated with breast
cancer was funded by Eli Lilly “in return for licensing privileges for
diagnostic kits and therapeutic products for BRCA1.”237 The funding
was therefore based on an exchange—the promise that Myriad would
be the first to sequence the breast cancer genes in exchange for
funding. The patents and licensing abilities associated with the rights
of patents provide much needed capital for biotechnology companies
to stay in business.
Weakening patents in the biotechnology sector risks negatively
impacting investments that bring products to the market
expeditiously—not only with respect to genetic sequences, but with
respect to any technology that affects patient care. Congress should
therefore craft legislation that addresses patient care without
threatening the property rights that biotechnology companies rely on
231.
232.
233.

See id.
Id. at S42.
See Christopher M. Holman, Biotechnology’s Prescription for Patent Reform, 5 J.
MARSHALL REV. INTELL. PROP. L. 318, 327-28 (2006).
234. See id. at 327.
235. See id. at 328.
236. See id. at 327-28.
237. Bryn Williams-Jones, History of a Gene Patent: Tracing the Development and
Application of Commercial BRCA Testing, 10 HEALTH L.J. 123, 129 (2002).
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in attracting investors.
B. There Is Little to No Evidence that Patents on Genetic
Sequences Have Hindered Future Research Through
Preemption and There Are Several Solutions Which Can
Address These Concerns Without a Blanket Exception to
Patentability
Although geneticists first focused on single gene associations to
one disease, scientists now realize that a specific gene accounts for
only a small risk of most diseases.238 Diagnostic companies are
therefore shifting their focus to “multiplex tests” which scan for
dozens of genes.239 The ever-lowering cost of genetic sequencing
suggests that even whole-genome sequencing for diseases will soon
be practical at a minimal cost.240 SACGHS found that patents on
specific genetic sequences may hinder development of multiplex
testing, parallel sequencing, and whole genome sequencing due to the
large amount of licenses that would need to be gathered in order to
implement the technology.241 Proponents against the patentability of
genetic sequences believe that this type of technology is negatively
impacted and in some cases preempted by the gene “patent thicket” of
many different private owners with unaligned interests.242 Negotiating
licenses to every relevant patent directed at a genetic sequence is
prohibitively expensive and there is little guarantee that every patent
holder would provide permission or a reasonable price.243 The “patent
thicket” potentially makes it infeasible to offer a product that
sequenced the genome or multiple genes due to the large number of
licenses or royalty fees needed in order to avoid patent
infringement.244
This fear is misplaced. The oft-quoted statistic that twenty
percent of the genome is patented is incorrect, and many of the
patents including Myriad’s would not be enforceable against the

238.
239.
240.
241.
242.
243.
244.

Sam Kean, The Human Genome (Patent) Project, 331 SCI. 530, 530 (2011).
Id.
Id.
SACGHS REPORT, supra note 213, at 3.
See Kean, supra note 237.
See SACGHS REPORT, supra note 213, at 3.
See Kean, supra note 237, at 530-31.
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technology and process used to sequence the whole genome.245 The
study where this statistic came from did not distinguish between
patent claims in which the isolated molecule is the invention and
claims in which a process is using the isolated molecule.246
Universities and nonprofits are less likely to enforce patents
aggressively and they own most patents on genes used in diagnostic
tests.247 Additionally, many of the genetic patents expired and others
have terminated for failure to pay fees.248 Finally, the remedy for a
holder of a single gene in a microarray technology that sequenced
thousands of genomes would be de minimus.249 With all of these
combined factors, the threat of a “patent thicket” inhibiting whole
genome sequencing or multiplex technologies is minimal.
In fact, there is no evidence that a “patent thicket” has stopped
companies from developing these types of technologies.250 For
example, Affymetrix is a company that should have experienced
considerable difficulty in the creation of their technology. Affymetrix
is developing a DNA chip with microarrays that might contain
thousands of genetic sequences.251 Yet, this supposed gene “patent
thicket” has not hindered Affymetrix’s development.252 Another
example is Foundation Medicine, which is planning to offer a
diagnostic test that searches for aberrations in a hundred or more
genes to determine how to treat cancer.253 Originally, Foundation
Medicine estimated that navigating the “patent thicket” would cost at
least thirty-five million dollars.254 However, after fully analyzing the

245. Christopher M. Holman, Will Gene Patents Impede Whole Genome Sequencing?:
Deconstructing the Myth that 20% of the Human Genome is Patented 1-12 (July 25, 2011),
available at http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1894715.
246. Id. at 2.
247. Kean, supra note 237, at 531.
248. Holman, supra note 244, at 13.
249. Whether the royalty is based on reasonable royalty, market share or lost profits, the
amount of damages would likely be so minimal for a holder of one patent that targets one gene
out of thousands and would not outweigh the large costs associated and years required in order
to reach a verdict in trial. See SACGHS REPORT, supra note 213, at 53.
250. See Christopher M. Holman, Patent Border Wars: Defining the Boundary Between
Scientific Discoveries and Patentable Inventions, 25 TRENDS IN BIOTECHNOLOGY 539, 540
(2007).
251. Id.
252. Id.
253. Kean, supra note 237, at 530.
254. Id.
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patents, the company found plenty of room in which to operate.255
Even if there is a small genetic “patent thicket”, it can be navigated in
several ways.
1. Patent Pool
A patent pool in which several patents are licensed for one price
can allow companies to easily navigate through patent thickets.256 A
patent pool gathers patents rights to multiple genetic sequences
together and provides a single license that bundles all of the rights
together.257 This would allow scientists, laboratories, and companies
working on multiplex and whole genome technologies to easily gather
permission from all patent holders, pay one pre-determined price, and
not fear liability in patent infringement suits.
However, in technologies where patent pools are usually used,
the technology is interdependent, and no single patent holder is
capable of marketing their patent technology independently of
others.258 For example, companies like Myriad can profitably market
their technology without joining the pool and therefore lack incentive
to join.259 A genetic patent pool may not operate as effectively as in
other technologies. Companies and scientists holding patent on
individual genes may have highly individually marketable genes that
would garner little profit, and therefore would have little incentive to
enter a patent pool. This would provide the same price no matter how
important the sequenced gene is.260 Some hope that multiple holders
to genetic sequences linked to the same specific condition will
recognize that it is crucial that each mutation be tested
simultaneously, and will therefore agree to enter a patent pool or
cross-licensing agreement.261
Despite potential difficulties in genetic patent pools, patentlicensing companies and structures have begun to emerge. For

255. Id. at 531.
256. SACGHS REPORT, supra note 213, at 55 (quoting Birgit Verbeure et al., Patent Pools
and Diagnostic Testing, 24 TRENDS IN BIOTECHNOLOGY 115, 117 (2006)) (A patent pool is
defined as an agreement “between two or more patent owners to license one or more of their
patents as a package to one another, and to third parties willing to pay the associated royalties.”).
257. SACGHS REPORT, supra note 213, at 3.
258. Id.
259. Id. at 56.
260. Id.
261. See id.
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example, MPEG LA,262 the “world leader in alternative one-stop
patent licenses” in April of 2011, created a genetic “supermarket”
from which a “one-stop patent license” can be purchased.263 The
company “announced a market-based initiative for a diagnostic
genetics patent licensing facility that addresses the market’s need for
nonexclusive access to patents for diagnostic genetics tests leading to
personalized medical solutions that save lives and reduce healthcare
costs.”264 If MPEG LA succeeds, the “patent thicket” in genetic
patents will be a thing of the past. In another example, one
biotechnology company posted a formula on their website that
outlined how much the company is willing to pay for every patented
gene sequenced from the thousands they sequence for every
customer.265
2. Patent Donation
Patent donation could provide a method for companies to donate
claims to isolated genetic sequences to the public; without
congressional interference into their companies or subject matter
limitations on patent law that might result in negative public
perception and uncertainty in other types of biotechnology patents.
Considering that most holders of genetic sequence patents allow basic
research on the genetic sequence to continue, and liberally license
genetic diagnostic testing to other facilities, a solution to the
controversial issue may itself be a controversial solution—patent
donation.
The genetic sequence patents could be donated to a nonpracticing entity or non-profit such as the Human Genome Project.
Alternatively, they could be donated to a “trust” created to hold the
genetic sequences. The donation of existing patents would generate
good public perception for the companies, and allow for better testing
and research. Patent donation would allow the owners of the genetic
sequences to generate good publicity, as opposed to the bad publicity

262. MPEG LA, http://www.mpegla.com/main/default.aspx (last visited Mar. 1, 2012).
263. Press Release, MPEG LA Launches Initiative to Make Gene Patents Available for
Diagnostic Testing, MPEG LA (Apr. 8, 2010),
http://www.mpegla.com/Lists/MPEG%20LA%20News%20List/Attachments/230/n-10-0408.pdf.
264. Id.
265. Kean, supra note 237, at 531.
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storm generated by Myriad’s business practices.266 Additionally,
patent donation could provide the companies a tax break for the
donation of these patents. Congress could enact legislation providing
a strong tax incentive to companies willing to donate their patents on
genetic sequences and other basic research tools to the public. A tax
break and the good public opinion generated by recognizing the
public need for access to genetic disease research, testing and
advancement might encourage companies to donate their genetic
sequence patents.
One issue with this method of encouraging companies to donate
genetic sequences to the public domain is that tax incentives do not
equal a mandate. A company like Myriad generates revenue by
holding a 20 year exclusionary property right on a diagnostic test that
affects a large amount of the national population. A tax incentive
would not measure up to the potential revenue generated by the
patent, especially for a company that has invested money in research
and development, lawyers, patent prosecution, patent maintenance
fees and possible litigation.
However, companies fearing increased negative perception and
possible court decisions negating genetic subject matter as patentable
may be better served in donating their patents on sequences while
maintaining their other patents. This allows the companies to quell
any dissatisfaction with the patenting of biological matter, while still
maintaining patents on genetic diagnostics (which are speculated to
be so broad as to not actually need a claim on the sequence itself).
This will ease any uncertainty that investors have in continued biotech
research, and it will ease public dissatisfaction and the risk of the
courts etching out sections of the biotech sector as unpatentable.
In conclusion, there is little evidence that the genetic “patent
thicket” exists, and even if there is a small thicket the effect has been
minimal. Potential solutions include patent pools, cross licensing, or
donation to the public. Companies have already started to implement
these services. Clearly, current patents on genetic sequences are not
significantly preempting research and do not justify a broad ruling
that all genetic sequences are unpatentable.

266.

See supra Part III.B.
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C. Better Patient Treatment Will Not Be Achieved Through
Invalidation of Patentable Subject Matter
Patient access to better quality care permeated the complaint in
Myriad.267 When patents create a sole provider of a genetic test, like
the Myriad test for BRCA1/BRCA2, patients’ access to that test is
limited based on price, the companies processing capacity, and health
insurance coverage. When there is only one provider, patients are
unable to receive a second opinion from an independent laboratory.
Quality control of a sole provider’s diagnostic test and improvements
in the methods is often set back, since no other independent lab is
available to process the sample and verify the results. Additionally,
insurance companies may not always deem it necessary for a patient
to receive the test or may not have an agreement with the company
providing the test. While these are significant issues, the invalidation
of a patent would not address these concerns. Invalidation of genetic
sequence patents would not guarantee that other companies would
offer the diagnostic test, accept medical insurance, provide a lower
rate, or provide quality assurance. These issues are not patent law
issues. Other, more narrowly tailored solutions that actually address
these concerns are outlined below.
1. Quality Control Through FDA Regulation
The quality and accuracy of diagnostic tests could easily be
monitored within existing regulatory framework. Several government
agencies are already involved in the oversight of genetic testing.268
The Center for Medicare and Medicaid Services (CMS) regulates
laboratory compliance under the Clinical Laboratory Improvement
Amendment of 1988.269 The Federal Trade Commission oversees the
advertising of diagnostic tests.270 The Food and Drug Administration
currently regulates “diagnostic devices” which are manufactured by
one company and then sold as a kit to another laboratory for genetic
testing.271 The FDA, however, does not regulate diagnostic tests that

267. See generally Complaint, supra note 59.
268. See
Genetic
Testing,
NAT’L HUMAN
GENOME
http://www.genome.gov/10002335 (last visited Sept. 22, 2011).
269. Id.
270. Id.
271. Id.
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are both manufactured and performed by the same laboratory—like
the Myriad test.272 The Myriad test for BRCA is currently marketed
directly to the medical community and the public, without any FDA
regulation or oversight.273 The FDA has held public meetings on
whether they should oversee these types of tests.274 The FDA has
indicated that they believe that these types of tests should fall under
their oversight.275 Greater FDA oversight will come with greater costs
in the research and development phase of a product, which only
strengthens the argument that patent protection is needed in order to
encourage investment in the industry.276
2. Quality Control Through Broader Experimental Use
Exception and Limited Liability Rule
A broader experimental use exception would also allow quality
assurance to take place in independent laboratories, without that
laboratory incurring liability. Many industrialized countries recognize
a much stronger experimental use exception to patent infringement
liability than the United States currently allows.277 There are several
strong policy arguments for a broader research exemption. Foremost,
the words in a patent often fail to fully explain the complete nature of
a biological invention.278 Additional reasons include: determining
how the patent works; whether it works as taught; how to improve it
and how to work around it.279 A more expansive research exemption

272. Id.
273. Id.
274. See generally FDA/CDRH Public Meeting: Oversight of Laboratory Developed Tests
(LDTs), Date July 19-20, 2010, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm212830.htm (last
visited Sept. 22, 2011).
275. See Dan Vorhaus, DTC Genetic Testing and the FDA: Is There an End in Sight to the
Regulatory Uncertainty?, GENOMICS LAW REPORT (June 16, 2011),
http://www.genomicslawreport.com/index.php/2011/06/16/dtc-genetic-testing-and-the-fda-isthere-an-end-in-sight-to-the-regulatory-uncertainty/.
276. See Kirell Lakhman, FDA Tells Lame-Duck SACGHS of LDT ‘Loophole,’ But New
Regs Could Beget More, GENOMEWEB (Oct. 5, 2010), http://www.genomeweb.com/blog/fdatells-lame-duck-sacghs-ldt-loophole-new-regs-could-beget-more; Kirell Lakhman, What Labs
Should Expect – and Demand – from FDA’s New LDT Strategy, GENOMEWEB (July 19, 2010),
http://www.genomeweb.com/node/945450.
277. Janice Mueller, No “Dilettante Affair”: Rethinking the Experimental Use Exception
to Patent Infringement for Biomedical Research Tools, 76 WASH. L. REV. 1, 5 (2001).
278. See Merz & Cho, supra note 56, at 203.
279. Id. at 207.
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is especially necessary in basic scientific research, where the success
of an experiment is largely regarded as reproducibility of results and
minimization of statistical error. It makes little sense to wait until the
expiration of a patent term to learn if the research actually works.
One option is to allow the development of new therapies and
diagnostics through the non-consensual use of the genetic sequences,
even if ultimately used for commercial purpose, by enforcing a
“liability rule.”280 The liability rule would compensate the patent
owner appropriately through an ex post royalty based on the
marketplace value of any new products developed through use of the
tool.281 This ex post royalty would allow the owner of a gene
sequence patent to be rewarded only when a profitable expansion of
his intellectual property had been discovered, while increasing the
public’s knowledge and furthering scientific process. It would also
have the added benefit of developing different types of diagnostic
tests that potentially could serve to increase precision of the tests that
are developed, while still returning profits to the owner of the patent
for their investment in sequencing the gene. Therefore, only
successfully marketed products would incur liability.
3. Safe Harbor for Second Opinions
In an amendment to the 2011 Patent Reform Act, the House of
Representatives introduced a “safe harbor for second opinions”
provision. The proposal created a new section 287(d) under the Patent
Act to establish a safe harbor for second opinion genetic diagnostic
testing providers,282 much like the safe harbor that already exists at
section 287(c) for medical practitioner performance of medical
activities.283 Although second opinions were one of the issues that the
ACLU identified in the patent suit against Myriad, they vehemently

280. Mueller, supra note 276, at 9-10.
281. Id. at 9-10.
282. Amendment to H.R. 1249, H.AMDT.491, 112th Cong. § 27 (June 23, 2011),
available
at
http://www.genomicslawreport.com/wp-content/uploads/2011/06/HR-1249Managers-Amendments.pdf; See also Dan Vorhaus, Update: Proposed Second Opinion Safe
Harbor for Genetic Diagnostic Testing Withdrawn, GENOMICS LAW REPORT (June 16, 2011),
http://www.genomicslawreport.com/index.php/2011/06/16/update-proposed-second-opinionsafe-harbor-for-genetic-diagnostic-testing-withdrawn/.
283. Amendment to H.R. 1249, H.AMDT.491, 112th Cong. § 27 (June 23, 2011); 35
U.S.C. § 287(c) (2006).
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opposed this amendment.284 The ACLU noted that “[t]he proposed
language would fail to block all patent holder objections to such
testing, fails to address the many other limitations on scientific
research arising out of the issuance of such patents, and risks allowing
gene patent holders to argue that Congress implicitly endorses the
validity of such patents.”285 Following this letter, the safe harbor
provision was removed.286 While this amendment failed, Congress
clearly does have the ability to create a second opinion safe harbor
that could apply to all diagnostic tests, but more importantly would
provide farther-reaching patient care reform than patent invalidation.
4. Second Opinions and Increased Access Through
Congressional Legislation:
Instead of throwing thousands of genetic patents into question
and fundamentally altering the national outlook on patentable subject
matter, Congress should consider narrower approaches in dealing
with the issue, such as excluding genetic diagnostic methods from the
patent protection while not completely excluding patents on genetic
sequences.287 Europe allows the patenting of isolated genes while
preventing the patenting of the diagnostic process such as comparing
genes to find mutations.288 The European patent statute reads,
“European patents shall not be granted in respect of . . . methods for
treatment of the human or animal body by surgery or therapy and
diagnostic methods practi[c]ed on the human or animal body.”289
This would allow for the concerns of sick individuals to be addressed
(the need for second opinions, better diagnostics, lower prices,
insurance coverage and access) while still rewarding biotechnology
companies for their investment in research.
In 2002, Representative Lynn Rivers introduced the Genomic
284. See, e.g., Letter from ACLU to Chairman Dreier, Chairman Smith, Ranking Member
Slaughter, and Ranking Member Conyers (June 15, 2011), available at
http://www.aclu.org/files/assets/final_ltr_re_opposing_wasserman_schultz_amendment_with_c
oalition_letter.pdf.; Vorhaus, supra note 281.
285. Letter from ACLU, supra note 283.
286. Vorhaus, supra note 281.
287. See Olga Bogard, Comment, Patenting the Human Body: The Constitutionality of
Gene Patents and Suggested Remedies for Reform, 63 SMU L. Rev. 1319, 1333-1334 (2010).
288. Id. at 1333.
289. Id. (quoting Convention on the Grant of European Patents, art. 53(c), Oct. 5, 1973, 13
I.L.M. 270 (as amended by Revision Act of Nov. 29, 2000) available at
http://www.epo.org/law-practice/legal-texts/epc.html).
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Research and Diagnostic Accessibility Act (GRDAA).290 GRDAA did
not affect the patentability of sequenced genes, but would have
provided limited exemptions from patent infringement liability for
certain uses of patented genetic sequences and information in the
context of basic research and diagnostic testing.291 The exemption
would have been very narrow, and may have had little practical effect
since pure non-commercial research is very rare, but it would have
provided an exemption from the remedies of a patent infringement
suit in the performance of genetic diagnostic testing.292 There is some
precedent for this type of exemption, since a medical practitioner is
exempted from liability for performing a medical or surgical
procedure.293 If genetic testing is considered to be a medical
procedure, than the exemption may still apply, but the person
providing the kit to conduct the test could still be held liable. The
narrow exceptions in GRDAA would have provided modest reforms
while addressing the primary concerns of genetic sequence patenting
by allowing broader access for genetic testing while still enforcing the
patent holders’ rights in all other circumstances.294
Compulsory licensing of human gene patents is another option
that may balance the competing interests of the need to encourage
companies to continue to pursue cutting edge research, protecting
fundamental scientific principles, and providing maximum access to
medical breakthroughs. Examples of compulsory licensing that could
be utilized include: “march-in” rights under the Bayh-Doyle Act,
refusal of injunctive relief under 35 U.S.C. §154(a)(1), and mandatory
licensing under the Clean Air Act.295
Congress could enact a type of compulsory license through
“march-in rights” similar to the rights the federal government
maintains under the Bayh-Doyle Act. March-in rights, like those

290. Genomic Research and Diagnostic Accessibility Act of 2002, H.R. 3967, 107th Cong.
(2002), available at http://www.gpo.gov/fdsys/pkg/BILLS-107hr3967ih/pdf/BILLS107hr3967ih.pdf; Christopher M. Holman, Recent Legislative Proposals Aimed at the Perceived
Problem of Gene Patents, SCITECH E-MERGING NEWS, 2 (2008),
http://www.abanet.org/scitech/biotech/pdfs/recent_legislative_chris_holman.pdf.
291. Holman, supra note 289.
292. Id.
293. Id. at 2-3.
294. Id. at 3.
295. Miri Yoon, Gene Patenting Debate: The Meaning of Myriad, 9 J. MARSHALL REV.
INTELL. PROP. L. 953, 969 (2010).
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under the Bayh-Doyle Act, allow commercialization and public
availability on federally funded inventions, which allows the
government to “march in” and require a recipient of funds to license
the invention under limited circumstances.296 The limited
circumstances include underutilized technologies that have been
developed through federally funded research.297 Since most basic
research is aided by federal funds,298 some genetic sequence patents
may already qualify for this type of protection. Expanding the
government’s “march-in” rights to genetic sequence patents could
solve several of the issues that patients currently face—lack of
insurance coverage, prohibitive cost of the test, inability to obtain a
second opinion, and quality control. This approach is not ideal
because it lends itself to discretionary abuse. If enacted, the “march-in
rights” provision would have to be narrowly tailored and carefully
implemented in order to avoid abuse of discretion and overuse.299
If the government enacts “march-in” rights, the patent owner
would still need to be assured of reasonable compensation when those
rights are exercised.300 One model of compulsory licensing through
“reasonable compensation” is the Clean Air Act, which was enacted
in the 1970s, and provided compulsory licenses for technologies
related to air pollution prevention and control.301 A Clean Air Act
compulsory license required that a patent that is critical to control air
pollution must be compulsory licensed if the attorney general
determines that the invention is not reasonably available, that there
are no reasonable alternatives, and that the unavailability of the
invention may result in a substantial problem of competition that
would create a monopoly in the technology area.302 The application of
a Clean Air Act like compulsory license would require the attorney
general, or some other designated government entity, to determine if
there was another way for the disease to be diagnosed, if the

296. Id. at 970.
297. Eric W. Guttag, Foaming at the Mouth II: My Alternative to the New But Inane
Becerra Bill, IP WATCHDOG (Apr. 15, 2010, 3:11 PM),
http://ipwatchdog.com/2010/04/15/foaming-at-the-mouth-ii-my-alternative-to-the-new-butinane-becerra-bill/id=10104/.
298. See generally Science and Engineering Indicators 2008, supra note 224.
299. Guttag, supra note 296.
300. Id.
301. Id.
302. Yoon, supra note 294, at 970.
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unavailability of another diagnosis creates a significant problem to the
public health, and the reasonableness of other alternatives.
Additionally, a reasonable royalty would be set and distributed to any
company found to qualify under this analysis. The threat of a
compulsory license or “march-in” rights would influence companies
to be more flexible in the licensing and access to their patents on
genetic sequences, and would rarely need to be invoked considering
most companies already provide reasonable access to genetic
sequence patents.
Court-implemented compulsory licenses could be enacted
through a refusal by the court system to provide injunctive relief
when infringement of a genetic sequence is found. Refusal to provide
injunctive relief under 35 U.S.C. §154(a)(1) allows a court to order
compulsory licensing if injunctive relief is improper when
infringement is found.303 This method of compulsory licensing
presents a problem because it is not a hard-line rule, so researchers
and the public will not know when a court will deem the facts of their
case to qualify for a compulsory license over injunctive relief.
Injunctive relief bypasses a ruling that genes are unpatentable by
taking the sting out of an infringement suit.
5. Health Care Reform to Address Patient Access and
Health Insurance Issues
The government at a state and federal level can institute
insurance reform mandates that could require coverage of diagnostics
tests.304 One of the key allegations in the ACLU’s complaint was that
patients cannot get tested because they were either uninsured or their
insurance would not cover the Myriad tests.305 A federal or state
mandate requiring insurance coverage for genetic diagnostic tests
303. Id.
304. See, e.g., Victoria Craig Bunce & J.P. Wieske, Health Insurance Mandates in the
States 2010, COUNCIL FOR AFFORDABLE HEALTH INS. (Oct. 20, 2010),
http://www.cahi.org/cahi_contents/resources/pdf/MandatesintheStates2010ExecSummary.pdf
(summary of state mandate health insurance initiatives); id. at 8 (Summary of federal mandates
in 2010). See generally The Patient Protection and Affordable Care Act, Pub. L. No. 111-148,
124 Stat. 119 (2010), available at http://www.gpo.gov/fdsys/pkg/PLAW111publ148/pdf/PLAW-111publ148.pdf.
305. Complaint, supra note 59, at 2 (“Many women at risk cannot even be tested because
they are uninsured and/or cannot afford the test offered by Myriad”); see also id. at 10 (“Myriad
will not accept the MassHealth Coverage”); see also id. at 12 (“Myriad would not accept her
insurance”).
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when a doctor recommends the test would better solve this complaint
than invalidation of genetic patents. Additionally, personal insurance
mandates, as in Massachusetts, could require that every individual
have health insurance, which would prevent uncovered individuals
from accessing the technology. However, requiring insurance to cover
the test or requiring an individual to carry health insurance would not
ensure that a sole provider would accept that health insurance
provider. In order to solve this issue, Congress would need to
implement a requirement that health insurance cover diagnostic tests.
Although this is an imperfect solution, it would have greater benefit
than the invalidation of a patent, because even if there are two or
more providers of a diagnostic test—it does not guarantee that any of
the providers will accept all health insurance or that any of the health
insurance providers will cover the test.
Additionally, Congress, independent health care community
regulators or the FDA could implement national standards that would
address the manner in which the test is administered, the way in
which the test is marketed, and the method in which the patient
receives counseling after negative or positive results are received.
In summary, there are several options to addressing patient
access to diagnostic technologies. Patent invalidation will not broadly
address all diagnostic technologies, which, regardless of subject
matter, carry the same access and quality issues. In fact, patent
invalidation will not guarantee that any of the access or care issues are
addressed. Therefore, these issues should not be addressed through
patent law, but through regulatory agencies and congressional
legislation with the ability and foresight to craft much needed reforms
in health care.
D. Myriad Should Not Have Unfair Access to Medical Samples
Based on Their Patents
Some proponents of invalidating Myriad’s patent assert that
Myriad’s patent allows the company “to collect annotated DNA
samples that would give it an unfair advantage over potential
competitors in discovering cures.”306 It could also give Myriad an
unfair advantage in discovering other BRCA mutations, due to the
large exclusive DNA sample size the company had immediate access

306.

Gold & Carbone, supra note 58, at S45.
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to.307 Effectively, this argument postulates that Myriad has a
competitive advantage in the patenting of other BRCA mutations
which could extend their monopoly.
However, Myriad contends that they never intended to create a
“private mutation database” and the company has extensively
contributed new mutations to the Breast Cancer Information Core
Mutation Database.308 There is some indication that they have already
stopped contributing to the database and publishing articles,309 but
this, like patient care and oversight of genetic testing, is not a patent
issue. A patient’s tissue sample should not be placed into a “mutation
bank” without informed consent. A patient’s autonomy necessitates
that the conflicting interest of a company providing a medical test and
the researcher trying to patent the next big invention should not
cross.310
First, to be placed in any type of “genetic mutation bank” a
patient would first need to fully consent to sharing their medical
information and tissue sample.311 An oversight committee could
require all genetic tissue banks to secure patient consent before
releasing information for research use, and that all information would
then go into a nationally recognized database and not a privately held
database. While a patent grants a negative right to a company to
exclude others from practicing their invention, it does not provide a
property right in an individual’s tissue sample. Legislation in genetic
confidentiality, patient autonomy, and health care records is not a new
area for Congress. Therefore, congressional legislation could easily
extend to the creation and implementation of a national genetic
database. Interestingly, if genetic sequences were ruled ineligible for
patent protection, the likelihood of shared data might decrease due to
the absence of a patent’s incentive to publicly disclose the research.

307. John Conley & Dan Vorhaus, How Will Myriad Respond to the Next Generation of
BRCA Testing?, GENOMICS LAW REPORT (Mar. 1, 2011),
http://www.genomicslawreport.com/index.php/2011/03/01/how-will-myriad-respond-to-thenext-generation-of-brca-testing/.
308. Gold & Carbone, supra note 58, at S45.
309. Conley & Vorhaus, supra note 306.
310. David Resnik, Are DNA Patents Bad For Medicine?, 65 HEALTH POL’Y 181, 192
(2002).
311. Id. at 191.
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IX. CONCLUSION
The patentability of genetic sequence is an interesting patent law
query precisely because the arguments are strong on both sides.
Patents are fundamental in the United States in order to further
scientific research. Without the patent race, the expansive
biotechnology sector would suffer. If patents on genetic sequences are
held unpatentable, investors in biotechnology and medical diagnostics
may worry that other types of biomedical patents will be excluded
from the patent bargain in the future. Uncertainty in the
biotechnology sector will have a negative impact on investments in
research and development. Fundamentally, quality of patient care and
access to diagnostic tests is a health care issue and patent law is not
the solution. Myriad’s business practices essentially dictated how
medical tests were distributed and regulated, how doctors were
trained, how patients received results, patient access, and patient
counseling. These are not issues for a private company or for patent
law. Congress must ensure that patients are not treated at the whim of
a company, but in a consistent and effectual manner that ensures
quality access to healthcare and counseling afterwards.

